Table 1. Characteristics of studies included in the meta-analysis.
| First author | Year | Country | case | Cancer type | Disease Stage | Detection | CIP2A positive(%) | Provided information on cutoff value | outcome endpoints | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|
| Dong ZQ[22] | 2011 | China | 90 | NSCLC | I-IV | IHC | 72.20 | score > 0(range of 0–12) | OS | 6 |
| Ren J[20] | 2011 | China | 85 | Renal cell carcinoma | I-IV | IHC | 70.00 | low (0–1) or high (2–3) | OS | 7 |
| C Bockelman[24] | 2011 | Finland | 73 | tongue cancer | T1-2N0M0 | IHC | 84.50 | low (0–2) or high (3) | OS | 7 |
| C Bockelman[33] | 2011 | Finland | 524 | serous ovarian cancer | I-IV | IHC | 58.60 | score >1(range of 0–3) | OS | 7 |
| He H[25] | 2012 | China | 136 | HCC | I-IV | IHC | 70.30 | low (0–4) or high (5–12) | OS, DFS | 6 |
| C Bockelman[37] | 2012 | Finland | 540 | colorectal cancer | I-IV | IHC | 87.90 | score >1(range of 0–3) | OS | 8 |
| Huang PZ[34] | 2012 | China | 136 | HCC | I-IV | RT-PCR | 77.90 | NA | OS, DFS | 6 |
| Teng HW[23] | 2012 | Taiwan | 167 | Colon Cancer | I-IV | IHC | 68.30 | H score ≥ 150(range of 0–300) | OS | 7 |
| Xu P[21] | 2012 | China | 97 | NSCLC | I-IV | IHC | 76.29 | score > 0(range of 0–12) | OS | 7 |
| Xu P[36] | 2013 | China | 57 | cholangiocarcinoma | I-IV | IHC | 78.95 | score > 0(range of 0–12) | OS | 6 |
| Sung WW[30] | 2013 | Taiwan | 98 | lung adenocarcinoma | I-III | RT-PCR | 50.00 | NA | OS | 7 |
| Wiegering A[27] | 2013 | Germany | 104 | Colorectal cancer | I-IV | RT-PCR | NA | above median fold expression value of 10,5 above normal tissue | OS | 8 |
| Wang L[26] | 2013 | China | 96 | pancreatic ductal adenocarcinoma | I-IV | IHC | 56.30 | the percentage of mild staining cells was greater than >10% of tumor cells | OS | 6 |
| Xue YJ[99] | 2013 | China | 117 | bladder urothelial cell carcinoma | Ta,T1-4 | IHC | 72.60 | score > 0(range of 0–12) | OS | 6 |
| Yu GZ[13] | 2013 | China | 1280 | breast cancer | I-IV | IHC | 77.60 | ≥7. of morphologically unequivocal neoplastic cells discretely expressed CIP2A in their cell cytoplasmic | DFS | 7 |
| Liu N[28] | 2014 | China | 280 | NPC | I-IV | IHC | 65.70 | score > 2(range of 0–4) | OS, DFS | 7 |
| Liu Z[32] | 2014 | China | 57 | lung cancer | I-IV | IHC | 63.79 | NA | OS | 6 |
| Flørenes VA(a)[29]# | 2015 | Norway | 51 | nodular melanoma | NA | IHC | 67.00 | score >2 in cytoplasm and >0 in nucleus(range of 0–9) | OS, DFS | 8 |
| Flørenes VA(b)[29]# | 2015 | Norway | 81 | Superficial spreading melanoma | NA | IHC | 68.00 | score >2 in cytoplasm and >0 in nucleus(range of 0–9) | OS | 8 |
| Chen KF[31] | 2015 | Taiwan | 220 | colorectal cancer | I-IV | IHC | 41.40 | H score ≥ 150(range of 0–300) | OS | 7 |
| Chen JS[12] | 2015 | China | 37 | advanced gastric cancer | >T2 | IHC | ≥50.00 | appreciable staining >5% of target cells | OS | 6 |
| Tang QZ[35] | 2015 | China | 131 | ccRCC | I-IV | IHC | 65.50 | score ≥ 145(range of 0–300) | OS, DFS | 6 |
| Cristóbal[14] | 2017 | Spain | 61 | TNBC | I-III | IHC | 72.10 | H score ≥ 150(range of 0–300) | OS | 8 |
IHC: Immunohistochemistry; RT-PCR: Real Time Polymerase Chain Reaction; NOS: Newcastle-Ottawa Scale; OS: overall survival; DFS: disease free survival; NSCLC: non-small-cell lung cancer; HCC: Hepatocellular Carcinoma; ccRCC: Clear Cell Renal Cell Carcinoma; NPC: Nasal Pharyngeal Cancer; TNBC: triple-negative breast cancer#; There were two parts of data (a and b) in each of the studies of Flørenes VA; NA: not available